Early experience shows beta-lactam therapeutic drug monitoring supports dose optimization in outpatient care, highlighting its feasibility.
We describe early experience with beta-lactam therapeutic drug monitoring (TDM) in a high-volume outpatient parenteral antimicrobial therapy (OPAT) program. In selected patients, TDM informed dose optimization and toxicity mitigation. Illustrative cases highlight feasibility and emerging lessons supporting beta-lactam TDM in outpatient care.
No takes yet. Share an insight, caveat, or question.
Barrett et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: